{"text": "Tyloxapol inhibits NF-kappa B and cytokine release , scavenges HOCI , and reduces viscosity of cystic fibrosis sputum .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Cystic fibrosis ( CF ) patients develop progressive cytokine - mediated inflammatory lung disease , with abundant production of thick , tenacious , protease - and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "In the search for a potential treatment , we have tested tyloxapol , an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B ( NK-kappa B ) , reduces resting secretion of the cytokine <extra_id_0> interleukin-8 <extra_id_2> Protein <extra_id_1> ( <extra_id_0> IL-8 <extra_id_2> Protein <extra_id_1> ) in cultured human monocytes , and inhibits lipopolysaccharide ( LPS ) - stimulated release of <extra_id_0> tumor necrosis factor-alpha <extra_id_2> Protein <extra_id_1> ( <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> ) , <extra_id_0> IL-1 beta <extra_id_2> Protein <extra_id_1> , <extra_id_0> IL-6 <extra_id_2> Protein <extra_id_1> , <extra_id_0> IL-8 <extra_id_2> Protein <extra_id_1> , <extra_id_0> granulocyte-macrophage colony-stimulating factor <extra_id_2> Protein <extra_id_1> ( <extra_id_0> GM-CSF <extra_id_2> Protein <extra_id_1> ) , and the eiconsanoids thromboxane A2 and leukotriene B4 ( LTB4 ) .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH ) .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Tyloxapol ( 0.05 to 0.1 % wt / vol ) effectively scavenges the oxidant hypochlorous acid ( HOCl ; 1 to 7.5 mM ) in vitro , and protects from HOCl - mediated lung injury in rats .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Tyloxapol also reduces the viscosity of CF sputum ( from 463 +/- 133 to 128 +/- 52 centipoise ) .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "We conclude that tyloxapol is potentially useful as a new antiinflammatory therapy for CF lung disease , and could possibly promote clearance of secretions in the CF airway .", "event": "<extra_id_0> <extra_id_1>"}
